Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Clinical Effect of Point Mutations in Myelodysplastic Syndromes
Rafael Bejar, Kristen E. Stevenson, Omar Abdel‐Wahab, et al.
New England Journal of Medicine (2011) Vol. 364, Iss. 26, pp. 2496-2506
Open Access | Times Cited: 1557

Showing 1-25 of 1557 citing articles:

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber, Attilio Orazi, Robert P. Hasserjian, et al.
Blood (2016) Vol. 127, Iss. 20, pp. 2391-2405
Open Access | Times Cited: 9112
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Döhner, Elihu H. Estey, David Grimwade, et al.
Blood (2016) Vol. 129, Iss. 4, pp. 424-447
Open Access | Times Cited: 5146
Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes
Siddhartha Jaiswal, Pierre Fontanillas, Jason Flannick, et al.
New England Journal of Medicine (2014) Vol. 371, Iss. 26, pp. 2488-2498
Open Access | Times Cited: 4106
Revised International Prognostic Scoring System for Myelodysplastic Syndromes
Peter L. Greenberg, Heinz Tuechler, Julie Schanz, et al.
Blood (2012) Vol. 120, Iss. 12, pp. 2454-2465
Open Access | Times Cited: 2861
Age-related mutations associated with clonal hematopoietic expansion and malignancies
Mingchao Xie, Charles Lu, Jiayin Wang, et al.
Nature Medicine (2014) Vol. 20, Iss. 12, pp. 1472-1478
Open Access | Times Cited: 1724
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
David P. Steensma, Rafael Bejar, Siddhartha Jaiswal, et al.
Blood (2015) Vol. 126, Iss. 1, pp. 9-16
Open Access | Times Cited: 1720
Clinical and biological implications of driver mutations in myelodysplastic syndromes
Elli Papaemmanuil, Moritz Gerstung, Luca Malcovati, et al.
Blood (2013) Vol. 122, Iss. 22, pp. 3616-3627
Open Access | Times Cited: 1711
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
William J. Gradishar, Benjamin O. Anderson, Ronald Balassanian, et al.
Journal of the National Comprehensive Cancer Network (2018) Vol. 16, Iss. 3, pp. 310-320
Open Access | Times Cited: 1597
Landscape of genetic lesions in 944 patients with myelodysplastic syndromes
Torsten Haferlach, Yasunobu Nagata, Vera Grossmann, et al.
Leukemia (2013) Vol. 28, Iss. 2, pp. 241-247
Open Access | Times Cited: 1420
Role of TET enzymes in DNA methylation, development, and cancer
K. Rasmussen, Kristian Helin
Genes & Development (2016) Vol. 30, Iss. 7, pp. 733-750
Open Access | Times Cited: 935
Acute myeloid leukemia ontogeny is defined by distinct somatic mutations
R. Coleman Lindsley, Brenton G. Mar, Emanuele Mazzola, et al.
Blood (2014) Vol. 125, Iss. 9, pp. 1367-1376
Open Access | Times Cited: 874
Clonal hematopoiesis in human aging and disease
Siddhartha Jaiswal, Benjamin L. Ebert
Science (2019) Vol. 366, Iss. 6465
Open Access | Times Cited: 835
Clonal Architecture of Secondary Acute Myeloid Leukemia
Matthew J. Walter, Dong Shen, Li Ding, et al.
New England Journal of Medicine (2012) Vol. 366, Iss. 12, pp. 1090-1098
Open Access | Times Cited: 751
Mutations and prognosis in primary myelofibrosis
A. M. Vannucchi, T L Lasho, Paola Guglielmelli, et al.
Leukemia (2013) Vol. 27, Iss. 9, pp. 1861-1869
Closed Access | Times Cited: 717
Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation
R. Coleman Lindsley, Wael Saber, Brenton G. Mar, et al.
New England Journal of Medicine (2017) Vol. 376, Iss. 6, pp. 536-547
Open Access | Times Cited: 682
The role of mutations in epigenetic regulators in myeloid malignancies
Alan H. Shih, Omar Abdel‐Wahab, Jay P. Patel, et al.
Nature reviews. Cancer (2012) Vol. 12, Iss. 9, pp. 599-612
Closed Access | Times Cited: 650
Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
Hui Yang, Carlos E. Bueso‐Ramos, Courtney DiNardo, et al.
Leukemia (2013) Vol. 28, Iss. 6, pp. 1280-1288
Open Access | Times Cited: 641
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet
Luca Malcovati, Eva Hellström‐Lindberg, David Bowen, et al.
Blood (2013) Vol. 122, Iss. 17, pp. 2943-2964
Open Access | Times Cited: 635
Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study
Ayalew Tefferi, Elisa Rumi, Guido Finazzi, et al.
Leukemia (2013) Vol. 27, Iss. 9, pp. 1874-1881
Open Access | Times Cited: 616
The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia
Adam S. Sperling, Christopher J. Gibson, Benjamin L. Ebert
Nature reviews. Cancer (2016) Vol. 17, Iss. 1, pp. 5-19
Open Access | Times Cited: 603
Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry
Alessandro Pastore, Vindi Jurinović, Robert Kridel, et al.
The Lancet Oncology (2015) Vol. 16, Iss. 9, pp. 1111-1122
Closed Access | Times Cited: 565
ASXL1 Mutations Promote Myeloid Transformation through Loss of PRC2-Mediated Gene Repression
Omar Abdel‐Wahab, Mazhar Adli, Lindsay M. LaFave, et al.
Cancer Cell (2012) Vol. 22, Iss. 2, pp. 180-193
Open Access | Times Cited: 549
Molecular International Prognostic Scoring System for Myelodysplastic Syndromes
Elsa Bernard, Heinz Tuechler, Peter L. Greenberg, et al.
NEJM Evidence (2022) Vol. 1, Iss. 7
Closed Access | Times Cited: 532
What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer
Julie-Aurore Losman, William G. Kaelin
Genes & Development (2013) Vol. 27, Iss. 8, pp. 836-852
Open Access | Times Cited: 530
TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients
Rafael Bejar, Allegra M. Lord, Kristen E. Stevenson, et al.
Blood (2014) Vol. 124, Iss. 17, pp. 2705-2712
Open Access | Times Cited: 522
Page 1 - Next Page

Scroll to top